Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2024-01-17 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于金宇生物技术股份有限公司2023年度向特定对象发行A股股票并在主板上市的补充法律意见书（四）
Regulatory Filings
2024-01-17 Chinese
致同会计师事务所（特殊普通合伙）关于金宇生物技术股份有限公司向特定对象发行股票申请文件的第二轮审核问询函有关财务会计问题的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed response from an accounting firm to a second round of review inquiries from the Shanghai Stock Exchange regarding a company's application for a private placement of shares. It includes extensive financial data, cash flow analysis, investment project descriptions, and funding gap calculations. The document is focused on financial accounting issues related to a specific financing event (private placement) and includes audit and verification procedures by the accounting firm. It is not a full annual or interim report, nor is it a simple announcement or certification. It is a specialized audit-related report addressing regulatory review questions about the company's financing and accounting. Therefore, it fits best under the category of Audit Report / Information (AR). 9M 2023
2024-01-17 Chinese
金宇生物技术股份有限公司关于2023年度向特定对象发行A股股票摊薄即期回报、填补回报措施及相关主体承诺（二次修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from a company regarding the impact of a specific issuance of A shares on immediate earnings dilution and the measures to compensate for this dilution. It includes financial assumptions, calculations of earnings per share before and after the issuance, risk warnings, the necessity and rationality of the issuance, and commitments from the board and major shareholders to uphold these measures. The document references regulatory guidelines and approvals from the China Securities Regulatory Commission. It is not a full annual or interim financial report but rather a capital/financing update related to a specific share issuance event and its financial impact. The document length is over 7,000 characters and contains substantive financial data and analysis related to the capital issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-01-12 Chinese
金宇生物技术股份有限公司2023年度向特定对象发行A股股票预案（二次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度向特定对象发行A股股票预案（二次修订稿）" which translates to "2023 Annual Proposal for Private Placement of A Shares (Second Revised Draft)" by Jinyu Bio-Technology Co., Ltd. The content extensively discusses the background, purpose, pricing, issuance details, shareholder structure changes, and regulatory approvals related to a specific issuance of shares to designated investors. It includes detailed sections on the issuance plan, shareholder information, agreements, use of proceeds, impact analysis, risk disclosures, and dividend policies. The document is a comprehensive plan or proposal for a capital raising event through a private placement of shares, not a simple announcement or a brief notice. It is not an annual report, earnings release, or management discussion. It is clearly a detailed capital/financing update regarding a specific share issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support a high confidence score.
2024-01-12 Chinese
金宇生物技术股份有限公司关于调整2023年度向特定对象发行A股股票方案（二次修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the adjustment of a 2023 plan for a specific issuance of A shares by the company. It details changes in the number of shares to be issued and the amount and use of the funds to be raised. The content focuses on capital raising activities and changes to the financing plan, without containing financial statements or comprehensive financial performance data. The document length is short (1755 characters) and it is clearly an announcement of a financing plan adjustment rather than a full financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-01-12 Chinese
金宇生物技术股份有限公司第十一届监事会第十一次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of resolutions passed at a supervisory board meeting of a company regarding adjustments to a planned private placement of A shares, including changes to the number of shares to be issued, the total amount of funds to be raised, and related agreements. It contains detailed descriptions of the meeting, voting results, and references to other announcements on the stock exchange website. The document is 3735 characters long, which is relatively short and primarily serves as a meeting resolution announcement rather than a full financial report or detailed prospectus. It does not contain actual financial statements or comprehensive financial data but rather decisions and approvals related to capital raising activities. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2024-01-12 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.